Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CRMD vs ALMS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–3 Matrix Metrics)
CRMD Overall Winner
6-Pillar Tally: CRMD 4 – 2 ALMS
Matrix Metrics: CRMD 6 – 3 ALMS
As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Alumis Inc. (ALMS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin), whereas ALMS carries 44.8/100 (HOLD) at $4.72 (N/M Forward P/E, -5938.1% operating margin).
- Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. ALMS 44.8/100 HOLD) and 1.22β · 103% Vol risk profile, whereas ALMS leads top-line expansion (-7.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8); meanwhile ALMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CRMD vs ALMS
CRMD
Head-to-Head Winner
CorMedix Inc.
$4.70
-2.59% 1D
Market Cap
$370.6M
TTM Revenue
$1.01B
Forward P/E
29.5x
Beta / 30D Vol
1.22β · 103% Vol
Unified Composite Score
55.5
HOLD
Tech 60.0
Fund 62.0
Flow 70.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
ALMS
Alumis Inc. Common Stock
$4.72
-8.07% 1D
Market Cap
$727.0M
TTM Revenue
$7.2M
Forward P/E
N/M
Beta / 30D Vol
2.24β · 84% Vol
Unified Composite Score
44.8
HOLD
Tech 33.0
Fund 51.0
Flow 67.0
Mom 74.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CRMD 4 – 2 ALMS)
1. Valuation Multiples
CRMD
Forward P/E
29.5x
N/M
Trailing P/E
2.4x
N/M
PEG Ratio
3.32x
N/M
EV / Revenue
N/M
96.7x
2. Growth & Scale
ALMS
Revenue Growth (YoY)
-47.7%
-7.7%
Earnings Growth (YoY)
+6.7%
+0.0%
TTM Revenue (USD)
$1.01B
$7.2M
Market Cap
$370.6M
$727.0M
3. Profitability & Quality
CRMD
Gross Margin
87.4%
100.0%
Operating Margin
41.0%
-5938.1%
Net Profit Margin
15.5%
0.0%
Return on Equity (ROE)
15.3%
-110.9%
4. Balance Sheet & Cash Flow
CRMD
Cash Generation (TTM)
$755M
-$352M
Cash Flow Margin
74.6%
N/A
Net Cash / Leverage
$514M Net Cash
$27M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ALMS
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
53.2% (22nd %ile)
108.0% (11th %ile)
Put/Call OI Skew
2.32x (Put-Skewed)
0.20x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
CRMD
OpEx & R&D Intensity
46.4% of Rev ($469M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CRMD (6) vs ALMS (3)| Institutional Metric | CRMD | ALMS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $370.6M | $727.0M | ALMS | |
| Trailing P/E Ratio | 2.4x | N/M | CRMD | |
| Forward P/E Ratio | 29.5x | N/M | CRMD | |
| Revenue Growth (YoY) | -47.7% | -7.7% | ALMS | |
| Operating Margin (TTM) | 41.0% | -5938.1% | CRMD | |
| Net Profit Margin | 15.5% | 0.0% | CRMD | |
| Return on Equity (ROE) | 15.3% | -110.9% | CRMD | |
| 52-Week Range Position | 1% ($5–$13) | 0% ($5–$31) | Tie | |
| Beta / 30D Volatility | 1.22β · 103% Vol | 2.24β · 84% Vol | ALMS | |
| Unified Institutional Score | 55.5 / 100 (HOLD) | 44.8 / 100 (HOLD) | CRMD | |
| Trailing 12M Revenue (USD) | $1.01B | $7.2M | Scale | |
| Gross Profit Margin (TTM) | 87.4% | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | 3.32x PEG · N/M EV/Rev | N/M PEG · 96.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $755M ($514M Net Cash) | -$352M ($27M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ALMS +10.91 pp
3M Horizon
CRMD +35.41 pp
6M Horizon
CRMD +38.09 pp
1Y Horizon
ALMS +43.83 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRMD Revenue | ALMS Revenue | CRMD Op. Margin | ALMS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2017 | $0M | N/A | -9997.4% | N/A | CRMD |
| FY2018 | $0M | N/A | -6250.4% | N/A | CRMD |
| FY2019 | $0M | N/A | -7416.3% | N/A | CRMD |
| FY2020 | $0M | N/A | -11378.4% | N/A | CRMD |
| FY2021 | $0M | N/A | -15417.5% | N/A | CRMD |
| FY2022 | $0M | N/A | -46819.9% | N/A | CRMD |
| FY2024 | $40M | N/A | -51.4% | N/A | CRMD |
| FY2025 | $310M | $20M | 48.2% | -1886.9% | CRMD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CRMD
BREAKDOWN
Current IV
53.2%
IV Percentile
22nd %ile
Put/Call OI Skew
2.32x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ALMS
BREAKDOWN
Current IV
108.0%
IV Percentile
11th %ile
Put/Call OI Skew
0.20x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact ALMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CRMD Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
46.4% of Rev ($469M)
90D Engineering Disclosures
0 Published
ALMS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CRMD vs ALMS Key Questions & Quantitative Answers
As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Alumis Inc. (ALMS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin), whereas ALMS carries 44.8/100 (HOLD) at $4.72 (N/M Forward P/E, -5938.1% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. ALMS 44.8/100 HOLD) and 1.22β · 103% Vol risk profile, whereas ALMS leads top-line expansion (-7.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8); meanwhile ALMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ALMS leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.01B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with ALMS at -7.7% YoY revenue growth and +0.0% YoY earnings growth on $7.2M TTM revenue (100.0% gross margin, -5938.1% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), CRMD cumulative revenue shifted +675.0% while ALMS shifted N/A. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($469M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ALMS.
CRMD screens cheaper on headline valuation multiples. CRMD trades at 29.5x Forward P/E, 2.4x Trailing P/E, 3.32x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas ALMS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 96.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus ALMS (-110.9% ROE) capital efficiency.
In options market volatility and institutional positioning, CRMD carries 53.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.32x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 103% Vol realized risk). By comparison, ALMS carries 108.0% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.20x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 84% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ALMS vs CRMD · Reverse Pair
CRMD vs VTVT
· Sector Peer
CRMD vs CAPR
· Sector Peer
ALMS vs ABVX
· Sector Peer
ALMS vs MBX
· Sector Peer
ALMS vs MLYS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem